157 related articles for article (PubMed ID: 11009623)
1. Structural effects of O-glycosylation on a 15-residue peptide from the mucin (MUC1) core protein.
Kirnarsky L; Prakash O; Vogen SM; Nomoto M; Hollingsworth MA; Sherman S
Biochemistry; 2000 Oct; 39(39):12076-82. PubMed ID: 11009623
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structural model of an alpha(2,6)-sialyl-t glycosylated MUC1 eicosapeptide under physiological conditions.
Dziadek S; Griesinger C; Kunz H; Reinscheid UM
Chemistry; 2006 Jun; 12(19):4981-93. PubMed ID: 16642533
[TBL] [Abstract][Full Text] [Related]
3. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
4. Conformational studies on the MUC1 tandem repeat glycopeptides: implication for the enzymatic O-glycosylation of the mucin protein core.
Kinarsky L; Suryanarayanan G; Prakash O; Paulsen H; Clausen H; Hanisch FG; Hollingsworth MA; Sherman S
Glycobiology; 2003 Dec; 13(12):929-39. PubMed ID: 12925576
[TBL] [Abstract][Full Text] [Related]
5. Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen.
Schuman J; Campbell AP; Koganty RR; Longenecker BM
J Pept Res; 2003 Mar; 61(3):91-108. PubMed ID: 12558945
[TBL] [Abstract][Full Text] [Related]
6. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
[TBL] [Abstract][Full Text] [Related]
7. Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies.
Spencer DI; Price MR; Tendler SJ; De Matteis CI; Stadie T; Hanisch FG
Cancer Lett; 1996 Feb; 100(1-2):11-5. PubMed ID: 8620429
[TBL] [Abstract][Full Text] [Related]
8. Role of glycosylation on the ensemble of conformations in the MUC1 immunodominant epitope.
Singh J; Her C; Supekar N; Boons GJ; Krishnan VV; Brooks CL
J Pept Sci; 2020 Jan; 26(1):e3229. PubMed ID: 31729101
[TBL] [Abstract][Full Text] [Related]
9. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
[TBL] [Abstract][Full Text] [Related]
11. Effects of glycosylation on fragments of tumour associated human epithelial mucin MUC1.
Braun P; Davies GM; Price MR; Williams PM; Tendler SJ; Kunz H
Bioorg Med Chem; 1998 Sep; 6(9):1531-45. PubMed ID: 9801825
[TBL] [Abstract][Full Text] [Related]
12. An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides.
Hashimoto R; Fujitani N; Takegawa Y; Kurogochi M; Matsushita T; Naruchi K; Ohyabu N; Hinou H; Gao XD; Manri N; Satake H; Kaneko A; Sakamoto T; Nishimura S
Chemistry; 2011 Feb; 17(8):2393-404. PubMed ID: 21264968
[TBL] [Abstract][Full Text] [Related]
13. Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIb and an O-glycosylated analogue.
Huang X; Smith MC; Berzofsky JA; Barchi JJ
FEBS Lett; 1996 Sep; 393(2-3):280-6. PubMed ID: 8814305
[TBL] [Abstract][Full Text] [Related]
14. Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions.
Grinstead JS; Koganty RR; Krantz MJ; Longenecker BM; Campbell AP
Biochemistry; 2002 Aug; 41(31):9946-61. PubMed ID: 12146959
[TBL] [Abstract][Full Text] [Related]
15. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.
Karsten U; Diotel C; Klich G; Paulsen H; Goletz S; Müller S; Hanisch FG
Cancer Res; 1998 Jun; 58(12):2541-9. PubMed ID: 9635576
[TBL] [Abstract][Full Text] [Related]
16. Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat.
Brokx RD; Revers L; Zhang Q; Yang S; Mal TK; Ikura M; Gariépy J
Biochemistry; 2003 Dec; 42(47):13817-25. PubMed ID: 14636048
[TBL] [Abstract][Full Text] [Related]
17. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides.
von Mensdorff-Pouilly S; Petrakou E; Kenemans P; van Uffelen K; Verstraeten AA; Snijdewint FG; van Kamp GJ; Schol DJ; Reis CA; Price MR; Livingston PO; Hilgers J
Int J Cancer; 2000 Jun; 86(5):702-12. PubMed ID: 10797294
[TBL] [Abstract][Full Text] [Related]
18. Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1).
Karsten U; Serttas N; Paulsen H; Danielczyk A; Goletz S
Glycobiology; 2004 Aug; 14(8):681-92. PubMed ID: 15115750
[TBL] [Abstract][Full Text] [Related]
19. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts.
Nishimori I; Perini F; Mountjoy KP; Sanderson SD; Johnson N; Cerny RL; Gross ML; Fontenot JD; Hollingsworth MA
Cancer Res; 1994 Jul; 54(14):3738-44. PubMed ID: 8033093
[TBL] [Abstract][Full Text] [Related]
20. Structural analysis of peptide substrates for mucin-type O-glycosylation.
Kirnarsky L; Nomoto M; Ikematsu Y; Hassan H; Bennett EP; Cerny RL; Clausen H; Hollingsworth MA; Sherman S
Biochemistry; 1998 Sep; 37(37):12811-7. PubMed ID: 9737858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
